Residency · La Jolla, CA
Sponsored by Scripps Clinic/Scripps Green Hospital
The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review.
Hepatology (Baltimore, Md.) · 2023 · 2,687 citations · Zobair Younossi
A multisociety Delphi consensus statement on new fatty liver disease nomenclature.
Journal of hepatology · 2023 · 2,696 citations · Zobair Younossi
A multisociety Delphi consensus statement on new fatty liver disease nomenclature.
Hepatology (Baltimore, Md.) · 2023 · 2,397 citations · Zobair Younossi
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.
The New England journal of medicine · 2024 · 1,637 citations · Zobair Younossi
Epidemiology of metabolic dysfunction-associated steatotic liver disease.
Clinical and molecular hepatology · 2025 · 691 citations · Zobair Younossi
A multisociety Delphi consensus statement on new fatty liver disease nomenclature.
Annals of hepatology · 2024 · 542 citations · Zobair Younossi
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association.
Diabetes care · 2025 · 272 citations · Zobair Younossi
American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD).
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2022 · 806 citations · Zobair Younossi